Company profilePharmaceutical#403 of 1,318 in Pakistan✓ No DRAP alerts

MISSION PHARMACEUTICALS

Pharmaceutical company · 41 brands · 62 molecules

Ranked #43 of 60 companies in Antithrombotic Agents

41 registered products 20 pharmaceutical brands 62 distinct molecules 0 DRAP alerts

Company overview

41
registered products
20
pharmaceutical brands
62
distinct molecules
2
therapeutic classes
0
DRAP alerts

MISSION PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 41 product registrations across 62 distinct molecules. Its portfolio is concentrated in Antithrombotic Agents and Antiinflammatory And Antirheumatic Products. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by MISSION

50 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antiinflammatory And Antirheumatic Products 2

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

49
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202549

Top molecules by brand count

Levofloxacin3 brands
Paracetamol ...... 250 Mg2 brands
Cefixime2 brands
Azithromycin2 brands
Paracetamol ...... 500 Mg1 brand
Cefixime ...... 400 Mg1 brand
Tramadol1 brand

Therapeutic classes

Antithrombotic Agents · 1Antiinflammatory And Antirheumatic Products · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official41 products · Rs 41.11 – Rs 24,668.11
Median across source: Rs 230.24

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

HIGH - Q INTERNATIONAL21 shared molecules
BIO LABS (PVT) LTD.21 shared molecules
SEARLE PAKISTAN (PVT.) LTD.21 shared molecules
IRZA PHARMA (PVT) LTD.20 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

MEDIATE PHARMACEUTICALS (PVT) LTD holds 98 molecules not in this portfolio
AcyclovirAlendronateAmlodipineAmoxicillinAmpicillinAmpicillin Base
SHAIGAN PHARMACEUTICALS (PVT) LTD. holds 122 molecules not in this portfolio
AlbendazoleAmlodipineAmlodipine BasylateAscorbic AcidAspirinBetamethasone
HIGH - Q INTERNATIONAL holds 124 molecules not in this portfolio
000 I.UAcetyl L-CarnitineAmlodipineAnastrozoleAprepitantArachis Oil

Get the full profile for MISSION

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.